Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

The FDA accepted Breyanzi's sBLA for relapsed/refractory marginal zone lymphoma, granting priority review with a PDUFA date of December 5, 2025. Breyanzi is a CAR-T cell therapy targeting CD19, with a ...

What Is Breyanzi, and Why Does It Matter? Breyanzi (lisocabtagene maraleucel) is a type of personalized cancer treatment called chimeric antigen receptor (CAR) T-cell therapy, which uses your modified ...

“The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the broadest range of B-cell malignancies ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who ...

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda The cohort included 103 patients (63.1% female, 36.9% ...

A Prescription Drug User Fee Act target date of December 5, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...

Primary cutaneous B-cell lymphoma encompass clinically heterogeneous entities. While primary cutaneous diffuse large B-cell lymphoma, leg type (pcDLBCL-LT) is aggressive, primary cutaneous follicle ...